BIOEMTECH

BIOEMTECH is a preclinical CRO based in Greece. Established in 2013, the company's mission is to facilitate the transition from ex vivo studies to in vivo molecular imaging by offering cost-effective solutions in terms of instrumentation and services. Their flagship product, the "eyes," represents the first desktop cameras capable of real-time imaging of PET and SPECT isotopes in mice. In addition to this groundbreaking technology, BIOEMTECH conducts comprehensive studies for assessing new compounds in their authorized laboratories, equipped with advanced facilities for in vivo imaging with microPET/SPECT/CT and optical imaging, radiochemistry, and in vitro analysis. Their client base includes universities and pharmaceutical companies, and the company holds accreditations for performing toxicological studies and handling radioisotopes for evaluating diagnostic and therapeutic radiopharmaceuticals.

Notably, the company has been actively involved in numerous projects including H2020, FET, ERA, ITN, and others. This commitment to collaboration and innovation has attracted a €400.00K Seed Round investment from Metavallon VC in 23 August 2019, underscoring the potential and promise of BIOEMTECH's pioneering approach to preclinical research and molecular imaging.